antivir
antimicrobi
compound
either
produc
live
organ
obtain
chemic
synthesi
inhibit
viral
replic
antivir
interfer
one
viral
life
cycl
stage
fig
includ
cell
attach
fig
cell
penetr
fig
viral
uncoat
fig
viral
genom
dnarna
replic
fig
matur
fig
viral
progeni
releas
fig
treatment
antivir
stop
viral
infect
thu
compound
repres
import
tool
complement
action
vaccin
unfortun
antivir
therapi
repres
ehrlich
refer
magic
bullet
caus
seriou
side
effect
host
virus
use
host
machineri
surviv
replic
henc
antivir
deleteri
effect
host
cell
current
envisag
antivir
compound
capabl
stop
viral
replic
give
patient
immun
system
time
neutral
erad
viral
pathogen
antivir
compound
initi
use
palli
care
ill
follow
natur
cours
true
antivir
start
use
plant
flavon
flavonoid
first
compound
antivir
activ
describ
well
sever
quinon
isoquinolin
deriv
earli
antivir
includ
phenanthridin
compound
twentythre
activ
influenza
viru
seven
display
suppress
action
rou
sarcoma
viru
infect
chick
earli
year
antivir
research
concentr
three
class
compound
substitut
benzimidazol
ribosid
dicarbonyl
thiosemicarbazon
antivir
sinc
remain
medic
import
regularli
subject
review
one
review
publish
hurst
hull
includ
refer
unfortun
earli
antimicrobi
clinic
interest
soon
becam
appar
compound
although
effici
virus
panacea
control
viral
infect
sinc
could
effect
particular
viru
close
relat
organ
earli
year
antivir
research
number
compound
use
attempt
control
viral
diseas
includ
urazol
relat
compound
orh
ydroxi
naphthalenesulfon
acid
deriv
acid
polym
inhibit
cellular
ribonucleas
plant
extract
also
use
antivir
partli
due
influenc
chines
medicin
one
exampl
aristoloch
acid
produc
aristolochiacea
aka
birthwort
famili
plant
alreadi
use
greek
roman
treat
urinari
problem
snake
bite
protect
action
aristoloch
acid
experiment
demonstr
rabbit
eye
infect
herp
simplex
compound
classifi
food
drug
administr
fda
potenti
toxic
substanc
due
carcinogen
mutagen
activ
deni
approv
food
supplement
common
strategi
search
antivir
drug
natur
make
extract
plant
anim
fungi
bacteria
assay
varieti
virus
way
woo
colleagu
test
plant
extract
herpex
simplex
viru
type
ii
unfortun
antivir
drug
thu
obtain
usual
toxic
mammal
report
lampi
cowork
use
still
limit
case
benefit
exceed
damag
drug
toxic
low
caus
harm
effect
use
synthet
antivir
drug
combin
natur
antibacteri
antivir
compound
lysozym
could
result
unexpect
benefit
increas
viral
rang
action
decreas
therapeut
dose
well
reduc
occurr
antiviralresist
strain
antivir
design
block
particular
step
viral
life
cycl
end
result
viral
progeni
gener
virus
howev
exhibit
high
mutat
rate
favor
appear
resist
viral
strain
thu
limit
use
antivir
compound
exampl
season
influenza
viru
strain
incorpor
mutat
neuraminidas
protein
thu
make
resist
antivir
tamiflu
oseltamivir
cid
also
describ
differ
way
obtain
antivir
compound
includ
varieti
natur
sourc
natur
compound
must
envis
complementari
chemic
synthes
antivir
two
main
purpos
lower
requir
therapeut
dose
ii
decreas
frequenc
emerg
antiviralresist
viral
strain
although
peptid
protein
review
structur
heterogen
contain
posit
charg
domain
allow
compound
adopt
amphipath
conform
locat
hydrophilichydrophob
interfac
amphipath
conform
believ
prerequisit
antimicrobi
activ
ultim
result
cell
membran
disrupt
addit
mani
protein
degrad
shorter
peptid
perhap
best
exampl
lactoferrin
see
section
enhanc
antivir
activ
fig
summari
cell
attain
antivir
state
requir
two
signal
pathway
result
activ
rnase
l
degrad
viral
cellular
mrna
oligoadenyl
synthas
oa
use
avail
atp
synthes
oligoadenyl
enzym
phosphodiesteras
activ
rnase
l
also
cleav
end
trna
result
activ
rnase
l
hydrolyz
singlestrand
rna
includ
cellular
mrna
although
unabl
hydrolyz
doublestrand
rna
b
protein
kinas
phosphoryl
major
protein
asubunit
initi
factor
phosphoryl
block
eukaryot
protein
synthesi
interferon
protein
produc
anim
cell
inhibit
viru
replic
isaac
lindenmann
report
embryon
hen
egg
challeng
orthomyxovirus
produc
substanc
call
interferon
novel
discoveri
open
new
line
research
virolog
current
accept
abil
produc
viral
interf
protein
acquir
late
vertebr
evolut
also
creat
dichotomi
viral
interfer
viral
interfer
mediat
interferon
ii
viral
interfer
mediat
interferon
year
saw
public
classic
paper
studi
mode
action
distribut
protein
found
produc
mani
anim
today
interferon
ifn
gene
far
describ
consid
signal
protein
cytokin
activ
immun
system
specif
pathway
activ
natur
killer
cell
macrophag
increas
express
major
histocompat
complex
antigen
order
elimin
infect
virus
even
tumor
interferon
synthes
higher
eukaryot
highli
coil
rna
mainli
respons
induc
synthesi
protein
fig
ifn
current
known
group
three
categori
type
ifn
type
ii
ifn
type
iii
ifn
type
ifn
formerli
known
acidresist
glycosyl
phosphoryl
protein
produc
induc
leukocyt
lymphoblast
cell
fibroblast
group
includ
subtyp
ifna
ifnb
ifnd
ifn
ifnf
ifnj
ifnm
ifn
ifnx
type
ii
ifn
also
known
immun
interferon
c
interferon
produc
induc
lymphoid
cell
lymphokineactiv
macrophag
tlymphocyt
activ
human
acidlabil
lipoprotein
span
amino
acid
encod
singl
gene
wherea
mous
counterpart
amino
acid
type
interferon
howev
induc
interleukinunrel
compound
phytohemagglutinin
concanavalin
tuberculin
compound
shown
trigger
interferon
synthesi
cultur
mous
spleen
cell
type
iii
ifn
origin
describ
antivir
protein
later
rediscov
earli
centuri
although
activ
ifn
group
less
character
type
ii
molecul
known
type
iii
ifn
encod
four
gene
type
iand
type
iiiifn
activ
follow
detect
microbeassoci
molecular
pattern
mamp
molecul
recogn
cell
innat
immun
system
tolllik
receptor
tlr
pattern
recognit
receptor
prr
report
stetson
medzhitov
monro
colleagu
recognit
trigger
phosphoryl
sever
transcript
factor
transloc
cell
nucleu
includ
interferon
regulatori
factor
irf
fact
play
import
role
transcript
ifna
gene
ifr
contain
conserv
ntermin
region
span
ca
amino
acid
specif
bind
interferon
consensu
sequenc
locat
upstream
interferon
gene
ubiquit
enzym
origin
million
year
ago
constitut
integr
part
innat
immun
system
multicellular
organ
first
report
nicol
laschtschenko
although
name
lysozym
alexand
fleme
intrigu
small
enzym
human
lysozym
molecular
weight
ca
kda
although
milk
lysozym
reach
kda
paradigmat
hen
egg
white
lysozym
hewl
kda
lysozym
one
intrigu
molecul
carri
varieti
function
metabol
live
creatur
rang
prokaryot
organ
higher
eukaryot
first
protein
fulli
sequenc
human
gene
found
locat
chromosom
contain
four
exon
case
hewl
fig
lysozym
present
nasal
mucu
tear
saliva
gastric
duoden
ileal
colon
secret
even
cerebrospin
fluid
human
infant
although
enzym
defin
muramidas
hydrolyz
glycosid
linkag
present
bacteri
peptidoglycan
lysozym
also
activ
bacteri
autolysin
act
chitinas
exhibit
antivir
activ
addit
amount
protein
human
gut
drastic
vari
depend
emot
estat
person
apart
exhibit
antibacteri
activ
lysozym
certain
circumst
control
develop
anim
virus
orthomyxovirus
summari
lysozym
group
type
accord
sequenc
similar
group
includ
chickentyp
hewl
clysozym
stomach
lysozym
goosetyp
lysozym
goos
eggwhit
lysozym
gewl
glysozym
phagetyp
lysozym
phage
type
bacteri
lysozym
insecttyp
lysozym
planttyp
lysozym
weaver
cowork
state
gewl
hewl
common
part
counterpart
convers
gewl
common
structur
element
occur
hewl
pattern
structur
similar
could
easili
arisen
diverg
evolut
common
precursor
would
expect
result
independ
event
evolut
although
lysozym
display
antivir
activ
action
appear
independ
bacteriolyt
activ
relat
posit
charg
induc
instabl
cellular
membran
demonstr
cisani
colleagu
author
found
hewl
stop
typic
cell
fusion
induc
herp
simplex
addit
neg
charg
molecul
drastic
reduc
antivir
activ
lysozym
activ
includ
anti
human
herp
viru
also
human
immunodefici
viru
hiv
use
lysozym
antivir
potenti
fact
low
risk
protein
toxic
even
overdos
cerven
cowork
studi
effect
lysozym
overdos
rat
unabl
identifi
evid
toxic
caus
enzym
inde
found
sign
differ
biolog
paramet
anim
fed
mgkgday
recombin
human
lysozym
compar
untreat
counterpart
undoubtedli
milk
uniqu
resourc
translat
medicin
recent
describ
contain
rich
pool
biolog
activ
molecul
demonstr
clinic
benefit
medic
applic
futur
mani
peptid
protein
antivir
activ
includ
section
alactalbumin
alactalbumin
lalba
nonenzymat
ca
bind
protein
fig
anoth
milk
protein
import
addit
clysozym
calciumbind
lysozym
belong
lysozym
gene
famili
regard
antimicrobi
role
lysozym
exocrin
secret
mammal
would
like
refer
reader
essenti
review
mckenzi
white
clysozym
lalba
share
similar
primari
sequenc
structur
fig
indic
probabl
evolv
common
ancestr
protein
approxim
amino
acid
conserv
protein
although
function
differ
indic
lalba
rare
abil
among
lysozym
bind
calcium
bind
calcium
lalba
involv
synthesi
lactos
mammal
enzym
present
gut
play
role
tumor
apoptosi
lalba
antivir
antitumor
antistress
properti
also
describ
anxiolyt
even
compound
lower
blood
pressur
prevent
diarrhea
review
see
zimecki
kruzel
milk
protein
fragment
display
enhanc
antivir
activ
modifi
simpl
radic
anhydrid
berkhout
colleagu
show
anhydridemodifi
lalba
potent
inhibit
replic
fig
conclud
hiv
inhibit
gener
properti
neg
charg
polypeptid
confirm
oevermann
cowork
report
differ
type
virus
test
herp
simplex
viru
type
far
sensit
modifi
compound
addit
recent
investig
indic
methyl
lalba
peptic
hydrolys
anticytomegalovir
activ
lalba
case
lysozym
effici
inhibit
hsv
virus
either
fulllength
protein
digest
tryptic
peptid
hsv
virus
caus
varieti
clinic
syndrom
herpet
kerat
import
caus
infect
blind
enceph
even
miscarriag
transplacent
viral
transmiss
fetu
hsv
larg
envelop
nucleirepl
virus
chemic
treat
use
nucleosid
analog
acyclovir
guanin
see
section
hsv
strain
howev
often
develop
antivir
resist
mutat
gene
code
thymidin
kinas
dna
polymeras
sitohi
colleagu
demonstr
either
methylesterifi
alactoalbumin
tryptic
peptid
deriv
stronger
antivir
hsv
virus
unmodifi
counterpart
author
propos
antivir
activ
could
involv
one
sever
follow
mechan
disrupt
viral
envelop
capsid
protein
constitu
compromis
capsid
integr
fig
ii
restrain
interact
viral
cellular
protein
essenti
viral
infect
fig
iii
compound
bind
neg
charg
viral
phosphoprotein
fig
inhibit
transcript
activ
immedi
earli
gene
fig
iv
antivir
attach
viral
dna
prevent
transcript
replic
fig
v
inhibit
hydrolyt
activ
herp
viru
proteas
essenti
capsid
format
fig
human
lalba
recent
success
clone
express
transgen
pig
recombin
protein
effici
inhibit
dipeptidyl
peptidaseiv
activ
suggest
alactoalbumin
could
serv
natur
precursor
dipeptidyl
peptidaseiv
inhibitor
could
therefor
use
control
unwant
viral
popul
intestin
suckl
piglet
lactoferrin
lactoferrin
lactotransferrin
multifunct
kda
glycoprotein
secret
innat
immun
factor
often
found
alongsid
lysozym
human
secret
saliva
milk
colostrum
etc
protein
also
synthes
specif
granul
insid
neutrophil
thu
part
inflammatori
respons
gener
mucos
epithelium
polymorphonuclear
leukocyt
releas
granul
neutrophil
respons
microbi
infect
includ
virus
hepat
c
viru
hcv
superti
cowork
demonstr
fe
lactoferrin
inhibit
rotaviru
replic
apolactoferrin
activ
deriv
prevent
primari
viru
attach
mammalian
cell
fig
lactoferrin
potent
inhibitor
revers
transcriptas
ic
near
lm
also
effici
inhibit
hepat
c
infect
prevent
bind
viral
ligand
cellular
receptor
fig
addit
lactoferrinderiv
peptid
enhanc
antivir
properti
lactoferrin
first
isol
sorensen
sorensen
bovin
milk
nonhaem
ironbind
peptid
belong
transferrin
famili
protein
lactoferrin
report
inhibit
respiratori
syncyti
viru
hepat
b
viru
hbv
adenoviru
polioviru
hantaviru
sindbi
viru
semliki
forest
viru
echoviru
enteroviru
rotaviru
ng
et
al
also
studi
antivir
activ
whey
protein
found
could
inhibit
hiv
revers
transcriptas
fig
proteas
integras
also
inhibit
casein
bovin
lalba
blactoglobulin
methylatedlalba
methylatedblactoglobulin
prevent
develop
cytomegaloviru
diseas
addit
either
methylatedlalba
methyl
ethyl
blactoglobulin
prevent
hsv
final
esterifi
betalactoglobulin
esterifi
lactoferrin
control
infect
caus
certain
orthomyxoviru
strain
influenza
swart
colleagu
report
nativ
lactoferrin
acyl
form
bind
loop
envelop
protein
fig
repres
like
mechan
action
compound
hiv
virus
virus
lethal
avian
influenza
viru
also
suscept
protein
bovin
lactoferricin
lactoferrampin
bovin
lactoferricin
first
antimicrobi
peptid
isol
lactoferrin
lactotransferrin
pepsin
digest
gener
long
cation
disulfid
crosslink
peptid
human
lactoferricin
counterpart
much
larger
amino
acid
display
lower
biolog
activ
bovin
counterpart
bovin
lactoferrampin
peptid
origin
suspect
antimicrobi
properti
hoek
colleagu
final
describ
antimicrobi
compound
van
der
kraan
cowork
peptid
span
amino
acid
trp
arg
bovin
lactoferrin
although
repres
natur
occur
protein
display
strong
antibacteri
candidacid
activ
although
antivir
activ
remain
unknown
yin
cowork
describ
author
report
second
put
antimicrobi
domain
lactoferrin
respons
antimicrobi
activ
domain
interact
glycerol
head
group
multilamellar
vesicl
follow
twostep
model
first
residu
peptid
adopt
amphipath
ahel
conform
cterminu
molecul
remain
rel
unstructur
conform
caus
membran
instabl
respons
antimicrobi
activ
compound
lactogenin
kda
isol
bovin
milk
display
limit
ribonucleas
activ
yeast
transfer
rna
trna
well
cleav
polyc
activ
protein
includ
inhibit
cellfre
translat
rabbit
reticulocyt
lysat
inhibit
integras
fig
moder
inhibit
revers
transcriptas
fig
weakli
inhibit
proteas
fig
lactogenin
name
character
glycyrrhizinbind
protein
phosphoryl
ckinas
fact
help
understand
vivo
mechan
action
protein
ye
ng
describ
milk
glycoprotein
appar
molecular
weight
kda
capabl
inhibit
hemagglutin
activ
soybean
agglutinin
protein
case
lactogenin
glycolactin
display
moder
rnase
activ
yeast
trna
ph
optimum
could
also
inhibit
cellfre
translat
rabbit
reticulocyt
lysat
mechan
action
made
like
glycolactin
would
display
antivir
activ
activ
demonstr
wang
cowork
found
glycolactin
succinyl
deriv
could
inhibit
revers
transcriptas
fig
follow
year
final
confirm
glycolactin
also
strong
inhibitor
proteas
fig
integras
fig
thu
inhibit
viral
cycl
viru
old
friend
biochemistri
student
protein
tradit
use
studi
dicarboxyl
basic
amino
acid
even
use
monolay
format
earli
year
review
pellegrini
cowork
anion
protein
kda
isoelectr
point
pi
abund
rumin
absent
human
although
tertiari
structur
homolog
human
serum
retinol
bind
protein
bactericid
peptid
releas
proteolyt
digest
endopeptidas
present
mammalian
gastrointestin
tract
simpl
chemic
modif
blactoglobulin
molecul
produc
peptid
antivir
activ
one
modif
format
anhydrid
produc
compound
block
cellular
entri
hiv
herpesvirus
via
cell
receptor
fig
addit
methyl
deriv
blactoglobulin
interfer
abil
either
human
cytomegaloviru
hcmv
human
influenza
viru
subtyp
gener
viral
progeni
furthermor
modifi
antivir
assess
safe
therapeut
use
human
associ
side
effect
patient
casein
casein
main
protein
mammalian
milk
constitut
ca
protein
content
bovin
milk
contain
sever
proteinac
varieti
phosphoprotein
bcasein
anoth
compon
phosphoglycoprotein
jcasein
uniqu
exhibit
oglycosyl
site
thr
thr
thr
thu
polypeptid
moieti
attach
glycan
structur
chang
secret
process
glycosyl
pattern
jcasein
present
colostrum
parturit
contain
one
neutral
oligosaccharid
alditol
three
acid
oligosaccharid
alditol
one
tri
one
tetra
one
pentasacchariditol
saito
colleagu
identifi
chemic
structur
glycan
gasliquid
chromatographymass
spectrometri
anom
analysi
nuclear
magnet
reson
found
galactosyl
report
human
bovin
jcasein
protect
properti
human
rotaviru
hrv
infect
major
etiolog
agent
sever
infantil
gastroenter
although
isa
cowork
carri
pioneer
work
inagaki
colleagu
describ
role
glycan
sialic
acid
nacetylneuramin
acid
antirotaviru
activ
jcasein
antihrv
activ
jcasein
found
due
olink
glycan
deglycosyl
jcasein
lack
antivir
properti
indic
whey
protein
display
activ
varieti
virus
semliki
forest
viru
adenoviru
hcmv
hiv
enteroviru
rotaviru
sindbi
viru
echoviru
papillomaviru
hantaviru
hsv
respiratori
syncyti
viru
influenza
viru
avian
influenza
viru
polioviru
hbv
hcv
earli
report
show
simpl
modif
lysozym
molecul
irradi
gener
deriv
differ
biochem
properti
author
howev
describ
biolog
activ
modifi
compound
short
later
anoth
lysozym
deriv
obtain
time
chemic
modif
protein
arginin
residu
phenylglyox
follow
lysozym
deriv
modifi
tyrosin
tryptophan
residu
ie
tyrosin
nitrat
nitrotyrosin
reduc
aminotyrosin
tryptophan
turn
modifi
reaction
sulfenyl
chlorid
new
lysozym
deriv
gener
modifi
lysin
residu
either
guanidin
acetyl
succinyl
maleyl
simpl
lysozym
modif
includ
addit
fluoresceinisothiocyan
chemic
convers
aspart
acid
catalyt
residu
hen
eggwhit
lysozym
homoserin
ozon
oxid
tryptophan
n
select
modif
aspart
acid
lysozym
carbodiimid
reaction
modif
enzym
catalyt
group
ethylenimin
research
lysozym
deriv
final
led
radic
perman
modif
protein
adpribosyl
lysozym
describ
kur
year
later
found
modif
polyanion
substanc
heparin
sulfat
polysaccharid
gener
deriv
capabl
inhibit
replic
howev
unexpect
find
support
previou
work
antivir
peptid
gener
lysozym
digest
lalba
shed
new
light
antivir
protein
work
oevermann
cowork
confirm
protein
fragment
obtain
naturallyoccur
protein
chemic
modif
exhibit
improv
antivir
activ
particular
tryptic
peptid
obtain
anhydridemodifi
bovin
serum
albumin
lalba
blactoglobulin
chicken
lysozym
success
test
herp
virusinfect
vero
cell
result
obtain
quit
promis
unfortun
peptid
cytotox
effect
vero
cell
plant
long
repres
good
sourc
antimicrobi
molecul
manner
mirror
pioneer
work
waksman
streptomycin
cid
product
streptomyc
speci
plant
found
sourc
antibiot
effect
gram
posit
gram
neg
bacteria
well
fungi
clearli
indic
plant
could
also
good
sourc
antivir
consequ
fischer
cowork
report
veget
tannin
display
virucid
antivir
effect
ragetli
weintraub
describ
proteinac
compound
dianthu
caryophyllu
could
drastic
inhibit
replic
cycl
tobacco
mosaic
viru
tmv
infect
nicotiana
glutinosa
albano
donato
report
similar
find
human
virus
poliovirus
echo
enter
cytopath
human
orphan
virus
sela
applebaum
among
pioneer
field
describ
product
antivir
substanc
plant
melissa
officinali
produc
cytotox
quinolin
alkaloid
camptotheca
acumin
contain
camptothecin
fig
cid
substanc
capabl
inhibit
dna
topoisomeras
bark
stem
antivir
includ
tannin
nontannin
polyphenol
officinali
alkaloid
fraction
narcissu
hymnem
acid
capabl
viral
modul
krmpotic
colleagu
report
isol
cryptopleurin
cid
antivir
alkaloid
boehmeria
cylindrica
urticacea
highli
activ
dna
anim
virus
although
compound
display
activ
rna
virus
test
coxsacki
polio
type
virus
van
den
bergh
cowork
review
publish
data
one
hundr
plant
extract
belong
genera
famili
found
eight
extract
exhibit
signific
antivir
activ
flavonoid
import
group
plantderiv
secondari
metabolit
antivir
activ
compound
describ
also
effect
cardiovascular
diseas
ulcer
inflamm
osteoporosi
diarrhea
arthriti
flavonoid
far
abund
polyphenol
human
diet
usual
found
glycosid
sometim
acylglycosid
fruit
veget
natur
occur
flavonoid
quercetin
fig
cid
naringin
fig
cid
hesperetin
cid
catechin
cid
test
sever
anim
virus
includ
polioviru
type
parainfluenza
viru
type
respiratori
syncyti
viru
differ
effect
display
depend
flavonoid
compound
target
viru
suggest
certain
specif
antivir
mechan
action
antivir
activ
flavonoid
soon
found
includ
adenovirus
rou
sarcoma
sindbi
pseudorabi
sever
acut
respiratori
syndrom
coronaviru
sarscov
influenza
viru
epigallocatechin
gallat
cid
also
known
fig
abund
catechin
tea
recent
shown
exhibit
broad
activ
varieti
unrel
virus
includ
dna
rna
virus
hcv
influenza
vaccinia
adenoviru
reoviru
vesicular
stomat
viru
therefor
open
possibl
develop
small
antivir
molecul
activ
two
largest
group
pathogen
human
virus
bind
glycosaminoglycan
ie
hsv
bind
sialoglycan
ie
influenza
virus
mechan
action
compound
base
inhibit
cellular
receptor
kinas
serinethreoninespecif
protein
kinas
akt
mitogen
activ
protein
kinas
mapk
thu
interf
cellular
signal
transduct
pathway
triterpen
consist
six
isopren
unit
squalen
prototyp
abund
plant
compound
ca
accord
dzubak
et
al
malinowska
et
al
play
varieti
role
cellular
metabol
sterol
precursor
display
antivir
activ
nine
triterpen
antivir
activ
dammaradienol
fig
cid
purifi
poehland
cowork
betulin
acid
cid
pentacycl
triterpenoid
fig
isol
bark
white
birch
tree
betula
alba
var
pubescen
antiretrovir
anticanc
activ
compound
inhibit
eukaryot
topoisomeras
deriv
dihydro
betulin
acid
display
strongest
biolog
activ
betulin
acid
report
caus
apoptosi
map
kinas
pathway
includ
caspas
activ
mitochondri
membran
alter
dna
fragment
platan
acid
fig
cid
isol
leav
trumpet
satinash
syzygium
claviflorum
fujioka
colleagu
anoth
pentacycl
triterpenoid
antiretrovir
activ
similar
mode
action
addit
neem
leav
azadirachta
indica
juss
contain
triterpenoid
exhibit
activ
group
b
coxsackievirus
seed
stem
caesalpinia
minax
good
sourc
rare
cassan
furanoditerpenoid
friedelan
triterpenoid
activ
human
parainfluenza
viru
type
viru
reactiv
even
long
period
latenc
nuclei
problemat
medicin
worldwid
caus
human
morbid
mortal
activ
epsteinbarr
viru
ebv
associ
diseas
infecti
mononucleosi
glandular
fever
well
cancer
hodgkin
lymphoma
burkitt
lymphoma
gastric
cancer
nasopharyng
carcinoma
fact
estim
close
quarter
million
cancer
case
worldwid
everi
year
due
reactiv
dna
viru
henc
prevent
ebv
viru
reactiv
could
result
reduc
even
elimin
infecti
mononucleosi
cancer
regard
compound
cid
triterpenoid
isol
camellia
oil
shown
display
strong
activ
viru
recent
flavaglin
triterpenoid
leav
aglaia
forbesii
use
antivir
also
promis
result
osorio
cowork
report
isol
nine
new
triterpen
cassin
xylocarpa
maytenu
jelskii
compound
alreadi
know
activ
hiv
etiolog
agent
aid
acquir
immun
defici
syndrom
human
target
transcript
factor
nfkb
nuclear
factor
kappalightchainenhanc
activ
b
cell
zinc
finger
protein
bind
gcrich
motif
present
mani
promot
antihiv
activ
import
despit
fact
hiv
character
diseas
yet
cure
remain
seriou
public
health
problem
chang
colleagu
also
report
euphorbia
neriifolia
produc
triterpenoid
stronger
activ
human
coronaviru
actinomycin
cid
argan
oil
argania
spinos
addit
contain
oleic
acid
cid
alinolen
acid
cid
palmit
acid
cid
stearidon
acid
cid
linol
acid
cid
myrist
acid
cid
also
contain
triterpenoid
deriv
could
potenti
use
antivir
particular
case
arganin
c
cid
repres
lead
compound
develop
new
antivir
human
enteroviru
infect
constitut
seriou
health
threat
children
year
age
caus
worldwid
neurolog
clinic
disord
affect
children
feet
hand
mouth
recent
two
novel
ganoderma
lucidum
triterpenoid
droxi
ganoder
acid
gltb
cid
fig
success
infect
triterpenoid
display
cytotox
human
addit
alvarez
cowork
found
lupenederiv
pentacycl
triterpenoid
bursera
simaruba
capabl
inhibit
replic
furthermor
kvasnica
colleagu
report
synthesi
medic
signific
pentacycl
triterpenoid
nitrogenand
sulfurcontain
heterocycl
display
antitumor
antivir
activ
conclud
incorpor
heterocycl
motif
triterpen
sometim
bring
new
mechan
action
increas
activ
better
pharmacolog
properti
make
area
heterocycl
triterpen
hot
topic
chemistri
activ
natur
compound
old
classic
method
extract
compound
plant
organ
acid
slowli
substitut
vitro
plant
callu
cultiv
biotransform
origin
microbialmedi
varieti
triterpenoid
appropri
antivir
properti
also
permit
optim
yield
qualiti
produc
standard
target
compound
new
technolog
success
appli
biotransform
oleanol
acid
rhizomucor
miehei
ursol
acid
syncephalastrum
racemosum
lupeol
mucor
rouxii
aspergillu
ochraceu
betulin
aspergillu
oryza
aspergillu
foetidu
final
betulin
acid
mycelia
sterilia
penicillium
citreonigrum
plant
often
express
viral
resist
follow
interact
pathogen
compound
avirul
product
gene
avr
cellular
receptorlik
plant
protein
resist
gene
product
r
trigger
cascad
downstreamtransduc
event
gener
resist
phenotyp
accord
levi
colleagu
repres
consensu
model
base
flor
geneforgen
theori
typic
exampl
r
protein
n
nicotiana
tabacum
introduc
tobacco
n
glutinosa
avr
counterpart
tmv
helicas
domain
viral
protein
part
viru
replicas
complex
sela
applebaum
suggest
plant
produc
interferonlik
protein
case
interferon
vertebr
could
gener
antivir
state
inde
human
interferon
revers
protect
plant
viral
infect
particularli
protect
sever
nicotiana
speci
tmv
infect
antivir
factor
identifi
glycoprotein
induc
tmv
poli
c
gener
nucleotid
similar
oligoisodenyl
see
interferon
section
turn
confer
antivir
activ
find
indic
plant
anim
probabl
share
common
viru
resist
pathway
inde
western
blot
analysi
crude
protein
extract
tobacco
leav
infect
tmv
polyclon
antibodi
human
binterferon
identifi
two
plant
protein
although
sequenc
peptid
obtain
display
signific
homolog
human
betainterferon
two
protein
character
follow
year
isoform
idea
plant
protein
display
antivir
activ
gain
forc
everi
day
confirm
previou
report
awasthi
found
small
protein
kda
isol
cuscuta
reflexa
strong
activ
varieti
virus
anoth
exampl
provid
readi
cowork
report
dodecandrin
cid
pokewe
antivir
protein
two
novel
ribosomeinhibit
protein
purifi
phytolacca
dodecandra
ph
americana
respect
display
strong
antivir
activ
forese
futur
expect
complet
bacteri
operon
routin
clone
nontransgen
express
use
construct
deriv
geminiviru
tomato
yellow
leaf
curl
viru
tylcv
platform
produc
antivir
metabolit
novel
technolog
express
rate
close
elimin
need
use
select
express
marker
earli
public
shope
report
fungu
penicillium
funiculosum
isol
guam
produc
substanc
therapeut
activ
mice
infect
swine
influenza
viru
product
activ
principl
errat
fungu
eventu
lost
properti
author
claim
penicillium
funiculosum
produc
second
substanc
call
helenin
clinic
activ
columbia
sk
encephalomyel
viru
shope
suggest
helenin
temporarili
interf
viru
neuroinvas
infect
mice
neither
mechan
action
chemic
structur
compound
unravel
time
although
author
found
crude
activ
prepar
helenin
contain
larg
proport
polysaccharid
final
shope
conclud
fact
discuss
thu
far
quit
appar
helenin
would
practic
valu
treat
natur
occur
outbreak
viru
diseas
resembl
experiment
sk
viru
infect
mice
year
later
report
statolon
ca
complex
anion
polysaccharid
rel
high
galacturon
acid
cid
content
produc
penicillium
stoloniferum
involv
interferon
product
anim
cell
henc
creat
antivir
state
year
later
fujii
colleagu
isol
oglycosyl
mannan
lentinu
edod
could
suppress
growth
ehrlich
tumor
mice
lentinu
edod
repres
first
medicin
macrofungu
enter
realm
modern
biotechnolog
therapeut
import
fungu
limit
antivir
properti
also
use
treatment
diseas
involv
weaken
immun
system
cancer
environment
allergi
fungal
infect
patient
suffer
frequent
flu
cold
bronchial
inflamm
heart
diseas
hyperlipidemia
includ
high
blood
cholesterol
hypertens
infecti
diseas
diabet
hepat
even
play
role
regul
urinari
incontin
dextran
sulfat
ca
glucos
homopolym
molecular
mass
da
contain
sulfur
sulfat
inhibit
replic
human
immunodefici
viru
also
retrovirus
mainli
block
viru
attach
host
cell
fig
retrotranscriptas
activ
fig
effect
virus
high
dose
toxic
patient
compound
test
antivir
activ
caus
cell
slowli
develop
antivir
state
suggest
polysaccharid
human
hydrolyz
display
indirect
mode
action
induc
cellular
antivir
respons
suggest
veigacrespo
villa
compound
includ
sulfat
polysaccharid
curdlan
cid
neutral
polysaccharid
schizophyllan
cid
scleroglucan
ca
betaglucan
branch
produc
schyzophyllum
commun
sclerotium
rolfsii
respect
well
sclerotia
pleurotu
tuberregium
sulfat
polysaccharid
either
agaricu
brasiliensi
mycelia
auricularia
auricula
enzym
hydrolyz
polysaccharid
ie
commonli
found
fungi
bacteria
plant
distribut
anim
kingdom
rather
limit
found
egg
digest
tract
echinoderm
frog
henc
found
primat
structur
gene
discov
human
mean
nonhydrolys
polysaccharid
molecul
present
human
immun
system
activ
unspecif
respons
includ
gener
antivir
state
sometim
mediat
increas
cinterferon
heparin
highli
sulfat
glycosaminoglycan
display
anti
activ
interf
bind
viral
glycoprotein
b
c
proteoglycan
cell
surfac
fig
blood
thin
effect
preclud
use
human
medicin
addit
fact
heparinlik
polysaccharid
extrem
rare
fungi
limit
use
sulfat
fungal
polysaccharid
antivir
appear
collater
effect
except
complex
fungal
polysaccharid
chitosan
chitin
chitosan
cid
known
year
antivir
activ
although
detail
mechan
action
remain
elus
antivir
action
could
relat
fact
chitosan
revers
disrupt
cellular
tight
junction
thu
facilit
access
antivir
drug
cell
perhap
even
antivir
protein
interferon
defensin
antimicrobi
peptid
produc
anim
respons
viral
infect
addit
mammal
troubl
metabol
process
chitosan
chitin
well
compound
linger
insid
bodi
henc
like
organ
deploy
varieti
countermeasur
includ
antivir
encount
complex
polysaccharid
fact
mammal
express
two
gene
chitinolyt
activ
chitotriosidas
prototyp
acid
chitinas
decreas
amount
circul
polysaccharid
enzym
associ
human
differ
syndrom
gaucher
diseas
liposom
lipid
storag
thalassemia
even
psychiatr
disord
full
report
enzym
human
see
veigacrespo
villa
li
cowork
describ
new
applic
chitosanbas
materi
prevent
control
influenza
viru
use
chitosan
function
sialyllactos
found
drastic
inhibit
viral
adsorpt
fig
chitosanconjug
bound
viral
hemagglutinin
high
affin
prevent
viral
attach
host
ciejka
et
al
recent
synthes
new
sulfon
deriv
poli
allylamin
hydrochlorid
ca
nsulfon
chitosan
test
influenza
b
virus
author
found
novel
molecul
could
inhibit
influenza
b
viru
assembl
insid
host
cell
fig
hyaluron
acid
cid
nonsulf
glycosaminoglycan
found
synovi
fluid
eye
vitreou
humor
common
connect
tissu
although
commonli
found
bacteria
rare
fungi
except
cryptococcu
medic
use
hyaluron
acid
includ
wound
heal
mouth
care
well
treatment
condit
joint
pain
keratoconjunct
asthma
gastriti
compound
addit
display
antivir
activ
varieti
dna
rna
virus
despit
posit
effect
fact
hyaluron
acid
could
enhanc
bloodbrain
barrier
permeabl
either
transcellularli
paracellularli
infect
phagocyt
consider
limit
medic
use
long
known
bacteria
produc
antivir
substanc
macrolid
antibiot
borrelidin
cid
produc
sptreptomyc
sp
recent
rediscov
name
streptomyc
heilongjiangensi
antivir
includ
ehrlichin
synthes
streptomyc
lavendula
abikoviromycin
cid
produc
sever
speci
streptomyc
violarin
cid
actinomyc
violac
myxoviromycin
cid
compound
produc
streptomyc
sp
target
orthomyxovirus
virocidin
cid
niromycin
ca
ca
actinomycet
extract
propionibacteria
vivomycin
cid
produc
streptomyc
feingold
cowork
suggest
brucella
abortu
produc
compound
also
present
e
coli
could
induc
antivir
state
via
interferon
product
unabl
character
compound
anoth
earli
public
glaser
et
al
report
rat
spleen
cell
cultur
bacteri
lipopolysaccharid
lp
exert
cytotox
activ
gross
viru
retroviru
caus
lymphoma
rat
whose
counterpart
human
human
cell
lymphotrop
viru
htlvi
well
known
lipopolysaccharid
major
outer
membran
compon
gramneg
bacteria
one
potent
activ
innat
immun
system
constitut
host
defens
invad
pathogen
includ
virus
helfgott
colleagu
found
lp
enhanc
express
secret
beta
interferon
human
fibroblast
thu
contribut
creation
antivir
state
enhanc
express
mediat
antivir
transcript
factor
nfkappa
b
former
member
stat
protein
involv
gene
upregul
signal
type
type
ii
type
iii
interferon
latter
protein
complex
control
dna
transcript
cytokin
product
cell
surviv
lp
produc
unexplain
effect
supplement
virusinfect
cell
addit
low
lp
concentr
induc
macrophagebind
viral
infect
cell
lp
also
exert
peculiar
effect
report
canaves
colleagu
found
lp
combin
vascular
endotheli
growth
factor
caus
strong
synergist
effect
protect
cerebr
malaria
caus
plasmodium
berghei
addit
recent
report
cellular
caspas
becom
activ
oligomer
upon
interact
lp
lead
varieti
cellular
effect
could
involv
gener
antivir
state
part
lp
molecul
monophosphoryl
deriv
lipid
cid
report
antivir
activ
howev
appear
due
adjuv
activ
formul
vaccin
inde
patil
colleagu
confirm
adjuv
activ
monophosphoryllipid
part
pulmonari
deliv
influenza
vaccin
howev
ignor
fact
lipid
induc
inflamm
mammalian
immun
system
even
picomolar
amount
trigger
activ
henc
lipid
consid
endotoxin
lipid
aderiv
molecul
howev
display
interest
properti
antivir
accordingli
ikeda
cowork
report
chemicallysynthes
lipid
analog
contain
acyl
side
chain
signific
antivir
activ
orthopoxvirus
serum
ifninduc
activ
nk
cell
activ
addit
compound
acyl
side
chain
protect
immunosuppress
mice
bacteri
compon
includ
cell
wall
even
peptidoglycan
gram
posit
bacteria
ie
bacillu
alcalophilu
activ
macrophag
natur
killer
cell
creat
antipoxvir
state
increas
ainterferon
level
antivir
state
differ
one
gener
lp
differ
bacteria
shown
winter
colleagu
author
treat
mice
intraperiton
inocul
bordetella
pertussi
lipopolysaccharid
found
creat
resist
rabi
viru
encephalomyocard
viru
semliki
forest
viru
herp
simplex
viru
wherea
lp
e
coli
vibrio
cholera
salmonella
typhimurium
salmonella
minnesota
highli
sulfat
e
coli
polysaccharid
deriv
effect
inhibit
capac
respiratori
syncyti
viru
infect
human
lp
caus
tolllik
receptor
induct
harm
immun
proinflammatori
gene
neg
effect
could
counteract
lpslike
molecul
extract
cyanobacterium
oscillatoria
planktothrix
although
stimulatori
per
se
act
select
antagonist
antivir
bacteri
lp
bacteri
exopolysaccharid
induc
cell
produc
varieti
cytokin
thu
result
protect
differ
virus
way
maugeri
colleagu
report
novel
extracellular
polysaccharid
thermotoler
bacillu
licheniformi
induc
antivir
state
product
ifngamma
ifna
tnfa
indic
antivir
effect
pbmc
relat
particular
cytokin
induc
bacteri
flagellin
globular
protein
molecular
mass
kda
depend
bacteri
type
shape
hollow
tube
constitut
main
compon
bacteri
flagellum
present
almost
mobil
bacteria
flagellin
also
found
unexpect
place
insid
bacteria
describ
part
bacillu
subtili
nucleoid
vijaykumar
colleagu
found
system
treatment
mice
purifi
flagellin
induc
serolog
histopatholog
side
effect
lp
even
though
still
protect
anim
challeng
radiat
viral
infect
although
mechan
respons
protect
role
clear
could
relat
affin
flagellin
toward
dna
apart
bacteri
compound
capabl
elicit
virucid
respons
review
also
varieti
bacteri
virul
factor
caus
host
tissu
patholog
stimul
mammalian
cell
produc
divers
array
cytokin
result
product
antivir
state
factor
classifi
henderson
cowork
four
famili
adhesin
aggressin
impedin
invasin
substanc
includ
antivir
action
confirm
sinc
virus
replic
either
cytoplasm
nuclei
eukaryot
cell
fig
avp
aveb
logic
approach
control
diseas
caus
avp
short
peptid
taken
eukaryot
cell
interfer
replic
cycl
viru
hand
aveb
enzym
ie
proteas
could
extracellularli
digest
either
total
partial
viral
capsid
would
render
nake
viral
nucleic
acid
suscept
degrad
environment
dnase
altern
exampl
stimul
antivir
state
within
host
cell
product
interferon
alreadi
consid
synopsi
use
enzybiot
combin
synthet
antivir
drug
appear
best
chanc
success
earli
treatment
viral
infect
favor
secondari
bacteri
infect
repeatedli
report
influenza
virus
streptococcu
pneumonia
haemophilu
influenza
antihcv
treat
patient
feglymycin
cid
antimicrobi
peptid
amp
isol
streptomyc
sp
dsm
capabl
inhibit
hiv
entri
cell
fig
target
viral
envelop
protein
melittin
cid
amphipath
ahel
amp
isol
european
honeybe
api
melifera
venom
mechan
action
involv
block
viruscel
fusion
fig
defensin
short
cation
nonglycosyl
peptid
origin
found
rabbit
human
neutrophil
term
extend
similar
amp
plant
insect
defensin
exhibit
broad
spectrum
action
bacteria
fungi
virus
antivir
properti
mani
defensin
relat
lectinlik
properti
instanc
recent
discov
human
adefensin
cid
inhibit
multipl
step
entri
fusion
fig
vitro
addit
sever
defensin
human
adefensin
inhibit
human
papillomaviru
hpv
infect
block
virion
releas
endocyt
vesicl
fig
also
activ
human
adenoviru
adv
stabil
viral
capsid
protein
prevent
capsid
disassembl
cell
bind
fig
hdefensin
famili
amp
relat
adefensin
found
nonhuman
primat
amp
display
improv
antivir
activ
protect
cell
infect
envelop
virus
includ
inhibit
viral
adhes
entri
egg
white
egg
ancient
chelonioidea
marin
turtl
caretta
caretta
report
contain
small
cation
protein
tewp
amino
acid
residu
six
halfcystein
strong
antivir
activ
rhabdovirus
ie
vesicular
stomat
viru
vsv
emerg
human
pathogen
chandipura
viru
although
also
exhibit
activ
gramneg
bacteria
ribotoxin
potenti
candid
includ
group
enzybiot
anim
virus
restrictocin
ribonucleas
mitogillin
one
first
ribotoxin
describ
produc
aspergillu
restrictu
inactiv
ribosom
restrictocin
belong
barnas
superfamili
constitut
larg
group
rnadegrad
enzym
amino
acid
long
ie
rnase
produc
varieti
fungi
sever
bacteria
ie
shigella
dysenteria
boydii
sonnei
e
coli
stec
produc
ribotoxin
shiga
toxin
inhibit
translat
apparatu
eukaryot
cell
also
display
potent
antivir
activ
ie
suppress
bovin
leukemia
virusrel
spontan
lymphocyt
prolifer
ribotoxin
preferenti
enter
virusinfect
cell
although
cellular
receptor
yet
identifi
cleav
uniqu
phosphodiest
bond
locat
larg
rrna
gene
known
sarcinricin
loop
lead
inhibit
protein
synthesi
apoptosi
fact
ribotoxin
first
produc
cyclic
phosphat
intermedi
via
transphosphoryl
reaction
consequ
intermedi
hydrolyz
correspond
phosphat
novel
ribotoxinderiv
antivir
immunotoxin
current
develop
lack
detriment
side
effect
gener
due
bind
abil
ribotoxin
ige
antibodi
cowork
report
character
hirsutellin
ribotoxin
span
amino
acid
produc
mite
fungal
pathogen
hirsutella
thompsonii
insecticid
antivir
activ
small
rna
plant
could
soon
applic
pharmacolog
antivir
well
known
plant
short
interf
rna
sirna
confer
intracellular
antivir
immun
thu
serv
natur
antivir
defens
mechan
elbashir
cowork
show
transfect
long
small
interf
rna
sirna
mammalian
cell
result
degrad
target
mrna
henc
silenc
gene
express
fig
year
later
gitlin
colleagu
report
sirna
elicit
specif
intracellular
antivir
resist
human
cell
suggest
novel
therapeut
strategi
human
virus
oppos
tradit
approach
use
chemic
antivir
follow
year
kapadia
et
al
report
short
interf
rna
could
interfer
rna
replic
hcv
fig
wu
cowork
show
infect
sever
acut
respiratori
syndrom
sar
caus
newli
discov
coronaviru
sarscov
could
control
approach
addit
lecelli
et
al
design
long
rna
capabl
control
retrovir
infect
therefor
rna
silenc
rna
interfer
approach
carri
small
rna
small
interf
rna
sirna
microrna
mirna
appear
success
control
viral
infect
nevertheless
despit
expect
creat
scientif
world
singl
drug
fomivirsen
cid
gcg
ttt
gct
ctt
ctt
ctt
thu
far
approv
food
drug
administr
approv
treat
cytomegalovirusinduc
eye
infect
acquir
immunodefici
syndrom
patient
work
shapiro
colleagu
sirna
interf
respons
repres
step
forward
author
clearli
demonstr
drosha
one
two
cellular
rnase
iii
dicer
drosha
fig
repres
uniqu
conserv
arm
cellular
defens
use
combat
viru
infect
field
applic
combin
short
interf
rna
adenovirus
express
porcin
c
interferon
appear
work
well
control
foot
mouth
diseas
viru
fmdv
swine
summari
follow
rna
virus
could
inhibit
use
new
antivir
strategi
human
respiratori
syncyti
viru
hrsv
human
parainfluenza
viru
hpiv
dengu
viru
hcv
polio
amantadin
hydrochlorid
cid
fig
proton
channel
blocker
success
use
treat
influenza
viru
infect
discov
davi
cowork
amantadin
virucid
drug
antivir
effect
produc
inhibit
viral
penetr
fig
drug
inhibit
proton
channel
henc
protein
dissoci
ribonucleoprotein
complex
acidif
fig
similar
mechan
action
describ
rimantadin
amethylladaman
tanemethylamin
hydrochlorid
cid
analog
amantadin
arbidol
umifenovir
dimethyla
mino
methyl
phenylthio
methyl
indol
hydrochlorid
monohydr
cid
synthet
drug
develop
russia
broad
spectrum
action
use
treat
influenza
viru
b
c
vitro
suppress
infect
ebola
viru
tacarib
arenaviru
human
herp
viru
hcv
adenoviru
parainfluenza
type
rhinoviru
type
polioviru
avian
coronaviru
infecti
bronchiti
viru
marek
diseas
viru
hbv
hcv
arbidol
also
inhibit
replic
multipl
viru
famili
medic
import
worldwid
block
virusmedi
fusion
target
cell
membran
fig
synthet
neuraminidas
inhibitor
nai
discov
edmond
collabor
compound
competit
inhibit
viral
neuraminidas
na
sialidas
ec
enzym
present
influenza
viru
b
respons
releas
new
viru
particl
infect
cell
fig
author
synthet
sever
nsubstitut
oxam
acid
display
na
inhibit
antiinfluenza
viru
activ
vitro
howev
compound
lost
antivir
activ
inject
chicken
embryon
egg
presum
due
oxam
acid
metabol
chicken
embryo
dana
acid
cid
nonselect
transitionst
analog
inhibitor
influenza
na
develop
dana
occupi
activ
site
enzym
inhibit
function
howev
compound
yet
demonstr
benefici
effect
anim
model
influenza
infect
zanamivir
acid
cid
fig
sialic
acid
analog
design
base
crystal
structur
influenza
viru
na
first
nai
approv
prophylaxi
treatment
influenza
infect
zanamivir
shorten
durat
influenza
symptom
display
prophylact
effect
influenza
patient
henc
reduc
influenzarel
complic
inhibitor
one
million
time
specif
viral
na
human
na
administr
inhal
mgdose
oseltamivir
ethyl
cid
fig
prodrug
carboxyl
acid
cid
potent
inhibitor
viral
na
oseltamivir
administr
oral
mgdose
absorpt
gastrointestin
tract
enzymat
convert
subsequ
penetr
bronchoalveolar
line
fluid
peramivir
pentan
carboxyl
acid
cid
highli
select
inhibitor
influenza
b
viru
na
describ
babu
collabor
peramivir
display
greater
inhibitori
potenc
viral
na
particularli
influenza
b
viru
na
either
zanamivir
oseltamivir
laninamivir
pyl
acid
diaminomethylideneamino
acid
cid
anoth
nai
develop
japan
effect
oseltamivirresist
influenza
viru
strain
esterifi
prodrug
octanoyl
cid
much
longer
halflif
laninamivir
zanamivir
well
improv
effici
idoxuridin
idu
deoxyuridin
cid
iodin
analog
deoxyuridin
cid
synthet
pursoff
idu
use
treatment
ocular
kerat
produc
hsv
compound
transform
triphosph
idu
incorpor
dna
inhibit
viru
replic
fig
idu
effect
vitro
dna
virus
includ
hsv
hcmv
vaccinia
viru
due
toxic
idu
administ
dermal
deliveri
howev
resist
compound
alreadi
document
acyclovir
aciclovir
guanin
cid
fig
one
promin
member
acycl
nucleosid
analog
famili
effect
treatment
varicellazost
ebv
cytomegaloviru
herp
b
virus
compound
synthes
howard
schaeffer
lilia
beauchamp
acyclovir
close
relat
natur
dna
compon
guanin
deoxyribosid
cid
acyclovir
triphosph
cid
inhibit
dna
polymeras
compet
natur
deoxyguanosin
triphosph
although
effect
unspecif
viral
specif
acyclovir
aris
fact
convert
activ
form
virusspecif
thymidin
kinas
present
healthi
cell
ribavirin
virazol
cid
analog
guanosin
cid
describ
broadspectrum
antivir
action
use
treatment
persist
infect
either
hcv
respiratori
syncyti
virus
ribavirin
report
produc
lethal
mutat
viru
genom
result
reduc
infect
zidovudin
zdv
bw
azidothymidin
azt
cid
fig
analog
thymidin
act
inhibitoraltern
substrat
hivencod
revers
transcriptas
limit
viral
replic
fig
zdv
phosphoryl
insid
cell
absorpt
triphosph
form
cid
bind
strongli
viral
revers
transcriptas
cellular
dna
polymeras
mechan
action
virusspecif
sinc
zvd
effect
hiv
hcmv
zdv
first
compound
use
treat
aid
didanosin
ddi
dideoxyino
sine
cid
zalcitabin
ddc
dideoxycytidin
cid
two
nucleosid
analog
develop
mitsuya
broder
compound
potent
inhibitor
hiv
replic
act
chaintermin
viral
dna
sinc
compound
support
nucleosid
phosphodiest
link
end
synthet
nucleosid
analog
includ
stavudin
didehydro
nevirapin
nvp
f
cid
benzodiazepin
nnrti
discov
boehringeringelheim
pharmaceut
hargrav
collabor
compound
result
random
screen
process
inhibitor
revers
transcriptas
rt
follow
leadoptim
process
nevirapin
noncompetit
inhibitor
rt
rt
human
dna
polymeras
first
nnrti
compound
approv
fda
compound
alloster
bind
tyrosin
residu
posit
unit
rt
efavirenz
efv
cid
fig
anoth
nnrti
discov
merck
research
laboratori
efv
offer
sever
advantag
nvp
treatment
aid
although
equal
effect
suppress
infect
includ
lower
mortal
lower
incid
aidsdefin
ill
avoid
appear
resist
efv
use
conjunct
antiretrovir
therapi
synthet
pi
antivir
drug
use
treatment
hiv
hcv
viral
proteas
essenti
viral
matur
fig
instanc
hiv
retrovirus
gag
gagpol
protein
must
cleav
form
matur
virion
protein
saquinavir
sqv
ro
cid
manufactur
roch
laboratori
peptidomimet
hydroxyethylamin
inhibitor
high
affin
hiv
proteas
half
maxim
effect
concentr
ec
compound
potent
sqv
howev
highli
inhibit
serum
protein
rtv
use
pharmacokinet
enhanc
sinc
boost
effect
antivir
block
degrad
cytochrom
cytochrom
enzym
system
respons
metabol
mani
drug
includ
nnrti
pi
henc
rtv
usual
administr
combin
antiretrovir
drug
lopinavir
lpv
cid
anoth
peptidomimet
pi
develop
abbott
laboratori
lpv
also
pharmacokinet
enhanc
properti
case
rtv
use
lopinavirritonavir
fix
dose
treatment
hivaid
darunavir
drv
aminobenzenesulfonyl
isobutylamino
pyl
carbam
acid
hexahydrofuro
ester
cid
fig
non
peptid
pi
develop
tibotec
bvba
dvr
effect
mutant
hivproteas
resist
pi
drv
therapeut
use
combin
rtv
cobicistat
cid
cytochrom
inhibitor
describ
previou
section
usual
strategi
new
antivir
develop
includ
highthroughput
smallmolecul
screen
platform
structurebas
design
target
viral
replic
mechan
howev
anoth
interest
approach
would
use
therapeut
interf
particl
tip
strategi
defect
interf
particl
dip
antibodyrecogniz
capsid
protein
could
employ
order
increas
suscept
viru
neutral
host
immun
system
sinc
genet
divers
emerg
resist
viral
variant
produc
errorpron
replic
viral
genom
approach
exploit
properti
protein
besid
function
abl
form
capsid
subject
select
replic
pressur
way
resist
nonresist
genom
envelop
chimer
capsid
contain
dip
normal
capsid
protein
strategi
direct
administr
dip
protein
genet
engin
viru
genom
encod
dip
employ
treatment
viral
infect
howev
sever
safeti
concern
studi
uncontrol
transmiss
modifi
viru
possibl
gener
unexpect
virul
strain
oncogen
transform
cell
one
success
exampl
nonantivir
drug
modif
didehydrocortistatin
dca
analog
natur
steroid
alkaloid
cortistatin
cid
ca
produc
marin
spong
corticium
simplex
dca
potent
suppressor
tatdepend
hiv
transcript
inhibit
replic
fig
nanomolar
level
addit
properti
dca
inhibit
viral
releas
latent
infect
cell
isol
highli
activ
antiretrovir
therapi
haart
treat
patient
suggest
compound
consid
altern
shock
kill
strategi
similar
manner
treatment
hiv
hcv
influenza
viru
employ
drug
cocktail
common
antivir
treatment
holist
approach
order
reduc
appear
resist
strain
allow
eventu
erad
viral
particl
infect
cell
organ
addit
combin
use
antivir
adjunct
therapi
base
use
antivir
combin
nonantivir
drug
eg
hyaluron
acid
employ
order
reduc
side
effect
increas
bioavail
tissu
deliveri
eg
brain
cerebrospin
fluid
placenta
activ
compound
pay
special
attent
implement
person
medicin
similar
result
also
obtain
conjug
antivir
ligand
allow
tissu
target
lipid
liver
accumul
polyethylen
glycol
order
increas
stabil
peptid
protein
domain
increas
activ
among
other
develop
new
antivir
compound
compris
sever
approach
among
emphas
studi
new
antivir
target
unravel
viru
viral
cycl
guid
trigger
immun
system
respons
modif
exist
sourc
combinatori
use
rediscoveri
old
drug
new
function
among
other
factor
must
taken
account
sinc
main
part
viral
resist
found
treatment
one
drug
inde
sever
antivir
report
work
especi
ancient
one
studi
resultori
point
view
mechan
action
often
remain
unclear
regardless
elaps
time
discoveri
new
drug
import
notic
still
larg
amount
antivir
yet
employ
forgotten
scientif
commun
